CoChat
Sign Up
Cited by 45

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Novel, activating KIT‐N822I mutation in familial cutaneous mastocytosis

Wasag, Bartosz, Niedoszytko, Marek, Piskorz, Anna, Lange, Magdalena, Renke, Joanna, Jassem, Ewa, Biernat, Wojciech, Debiec-Rychter, Maria, Limon, Janusz·2011·Experimental Hematology
DOI 10.1016/j.exphem.2011.05.009
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.exphem.2011.05.009

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 22

  1. Garcia-Montero, 2006, KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients, Blood, 108, 2366, 10.1182/blood-2006-04-015545 · DOI
  2. Wilson, 2011, Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis, Haematologica, 96, 459, 10.3324/haematol.2010.031690 · DOI
  3. Beghini, 2001, Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa, Cancer, 92, 657, 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D · DOI
  4. Hartmann, 2005, Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis, Gastroenterology, 129, 1042, 10.1053/j.gastro.2005.06.060 · DOI · Paper page
  5. Tang, 2004, A germline mutation in KIT in familial diffuse cutaneous mastocytosis, J Med Genet, 41, e88, 10.1136/jmg.2003.015156 · DOI · Paper page
  6. Zhang, 2006, A novel K509I mutation of KIT identified in familial mastocytosis—in vitro and in vivo responsiveness to imatinib therapy, Leuk Res, 30, 373, 10.1016/j.leukres.2005.08.015 · DOI · Paper page
  7. Lombardo, 2004, Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays, J Med Chem, 47, 6658, 10.1021/jm049486a · DOI
  8. Dewaele, 2008, Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation, Clin Cancer Res, 14, 5749, 10.1158/1078-0432.CCR-08-0533 · DOI
  9. Shah, 2006, Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis, Blood, 108, 286, 10.1182/blood-2005-10-3969 · DOI
  10. Mital, 2011, A case of mast cell leukemia with exon 9 KIT mutation and good response to imatinib, Eur J Haematol, 86, 531, 10.1111/j.1600-0609.2011.01598.x · DOI
  11. Debiec-Rychter, 2005, Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants, Gastroenterology, 128, 270, 10.1053/j.gastro.2004.11.020 · DOI
  12. Kemmer, 2004, KIT mutations are common in testicular seminomas, Am J Pathol, 164, 305, 10.1016/S0002-9440(10)63120-3 · DOI
  13. Lux, 2000, KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors, Am J Pathol, 156, 791, 10.1016/S0002-9440(10)64946-2 · DOI
  14. Shimada, 2007, N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group, Leukemia, 21, 2218, 10.1038/sj.leu.2404766 · DOI
  15. Thalheimer, 2008, Familial gastrointestinal stromal tumors caused by the novel KIT exon 17 germline mutation N822Y, Am J Surg Pathol, 32, 1560, 10.1097/PAS.0b013e318172ce6f · DOI
  16. McDonnell, 2011, V559A and N822I double KIT mutant melanoma with predictable response to imatinib?, Pigment Cell Melanoma Res, 24, 390, 10.1111/j.1755-148X.2010.00822.x · DOI
  17. Carballo, 2005, Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation, Am J Med Genet A, 132, 361, 10.1002/ajmg.a.30388 · DOI
  18. Yang, 2010, Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations, Blood, 116, 1114, 10.1182/blood-2009-06-226027 · DOI
  19. Beghini, 2005, STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade, Exp Hematol, 33, 682, 10.1016/j.exphem.2005.03.007 · DOI
  20. Guo, 2007, Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor, Clin Cancer Res, 13, 4874, 10.1158/1078-0432.CCR-07-0484 · DOI
  21. Verstovsek, 2008, Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis, Clin Cancer Res, 14, 3906, 10.1158/1078-0432.CCR-08-0366 · DOI
  22. Ustun, 2009, Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V, Leuk Res, 33, 735, 10.1016/j.leukres.2008.09.027 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wasag, B., Niedoszytko, M., Piskorz, A., Lange, M., Renke, J., Jassem, E., Biernat, W., Debiec-Rychter, M., & Limon, J.
Venue
Experimental Hematology
Publisher
Elsevier BV
Published
2011-08
Volume
39
Issue
8
Pages
859-865.e2
ISSN
0301-472X
DOI
10.1016/j.exphem.2011.05.009
Cited by
45
References
2
Language
en
Licence
Funders
  • Life Raft Group (M.D.-R.)
  • Fonds voor Wetenschappelijk Onderzoek Vlaanderen (G.0589.09, M.D.-R.)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review